Z-VDVAD-FMK: Irreversible Caspase-2 Inhibitor for Apoptosis Research

Executive Summary: Z-VDVAD-FMK (benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone, SKU A1922) is an irreversible inhibitor of caspase-2, a cysteine protease central to mitochondria-mediated apoptosis (APExBIO). It covalently binds the active site of caspase-2, preventing its proteolytic activity and downstream events such as cytochrome c release (Padia et al., 2025). The inhibitor demonstrates cross-reactivity with caspases 3 and 7 and is validated in multiple cell models for apoptosis and caspase signaling pathway studies. Z-VDVAD-FMK is soluble at concentrations ≥34.8 mg/mL in DMSO and used at 25–100 μM in cell-based assays, with workflows optimized by APExBIO for reproducibility. This article details mechanism, evidence, applications, integration, and limits, extending prior resources with a focus on experimental boundaries and updated workflows.

Biological Rationale

Caspases are cysteine proteases essential for executing apoptosis and other forms of programmed cell death. Caspase-2 is one of the earliest caspases activated in response to cellular stress, acting upstream of mitochondrial cytochrome c release. Its activation leads to DNA fragmentation, phosphatidylserine exposure, and poly(ADP-ribose) polymerase (PARP) cleavage. Dysregulation of caspase-2 and related pathways is implicated in cancer, neurodegenerative diseases, and immune responses (Padia et al., 2025). Selective inhibition of caspase-2 enables mechanistic dissection of apoptosis and the interplay between intrinsic and extrinsic cell death pathways. Z-VDVAD-FMK provides a chemical genetic approach for distinguishing caspase-2-dependent events from parallel or compensatory mechanisms (CyclizineBio), clarifying roles in tumorigenesis, neurodegeneration, and cell stress models.

Mechanism of Action of Z-VDVAD-FMK

Z-VDVAD-FMK is a peptide fluoromethyl ketone derivative that acts as a suicide substrate for caspase-2. It enters cells and irreversibly alkylates the active-site cysteine of caspase-2 via its fluoromethyl ketone moiety, thereby blocking substrate cleavage and downstream proteolytic cascades. This prevents cytochrome c release from mitochondria and inhibits subsequent caspase activation steps, including caspase-3 and caspase-7 (APExBIO). In endothelial cells, Z-VDVAD-FMK reduces oxyhemoglobin-induced apoptosis by attenuating caspase-2 and caspase-3 activities, DNA fragmentation, and PARP cleavage. The specificity is determined by the peptide sequence (Val-Asp-Val-Ala-Asp), which mimics the preferred cleavage motif of caspase-2 but can also interact with related aspartate proteases.

Evidence & Benchmarks

• Z-VDVAD-FMK irreversibly inhibits caspase-2 activity in cell-free and cell-based systems, with IC₅₀ values in the low micromolar range (Padia et al., 2025, DOI).
• It blocks mitochondria-mediated apoptosis, as measured by reduced cytochrome c release and decreased PARP cleavage in Jurkat T-lymphocytes treated at 25–100 μM for 1–22 hours (APExBIO).
• In endothelial models, Z-VDVAD-FMK attenuates oxyhemoglobin-induced DNA fragmentation and caspase activity, supporting its utility in oxidative stress paradigms (Cytochrome C Pigeon).
• The compound exhibits cross-reactivity with caspases 3 and 7, but does not significantly inhibit caspase-1 or non-caspase proteases under standard conditions (Z-VDVAD-FMK.com).
• Storage at -20°C in DMSO preserves activity for short-term use; long-term storage leads to degradation and loss of inhibitory potency (APExBIO).

This article extends the scenario-driven exploration in Cytochrome C Pigeon by providing an updated synthesis of evidence on cross-caspase specificity and practical limits in complex models. It also clarifies troubleshooting and workflow integration not fully addressed in Z-VDVAD-FMK.com, focusing on standardization and storage stability.

Applications, Limits & Misconceptions

Z-VDVAD-FMK is widely used for:

• Apoptosis assays in cancer cell lines (e.g., Jurkat, HeLa) to dissect mitochondrial and caspase signaling pathways.
• Evaluating mitochondrial cytochrome c release inhibition and PARP cleavage in neurodegenerative disease models.
• Benchmarking caspase-2 versus caspase-3/7 dependence in cell death mechanisms.
• Validating caspase activity measurement protocols where irreversible inhibition is required for endpoint readouts.
• Studying the downstream effects of caspase-2 inhibition in host-pathogen and oxidative stress responses (AH6809.com).

Common Pitfalls or Misconceptions

• Non-selectivity at high concentrations: At concentrations above 100 μM, Z-VDVAD-FMK may inhibit caspase-3 and -7, confounding interpretation of caspase-2-selective effects.
• Lack of effect on pyroptosis: Z-VDVAD-FMK does not inhibit caspase-1 or pyroptotic cell death (e.g., in HOXC8 depletion models), as shown in NSCLC studies (Padia et al., 2025).
• Insolubility in aqueous buffers: The compound is insoluble in water and ethanol; improper dissolution can result in loss of activity.
• Long-term storage instability: Prolonged storage, even at -20°C, leads to reduced potency and increased degradation products.
• Not suitable for in vivo therapeutic studies: Z-VDVAD-FMK is for research use only and has not been validated for pharmacokinetics, toxicity, or therapeutic efficacy in animal models.

Workflow Integration & Parameters

For optimal use of Z-VDVAD-FMK (APExBIO, SKU A1922):

• Prepare stock solutions at ≥10 mM in DMSO with gentle warming and ultrasonic agitation to ensure full dissolution.
• Aliquot and store at -20°C; avoid repeated freeze-thaw cycles and use within 2–4 weeks for maximal activity.
• For cell-based assays, dilute into culture medium to achieve final concentrations of 25–100 μM; maintain DMSO at ≤0.2% (v/v) to minimize cytotoxicity.
• Incubate cells for 1–22 hours depending on the model and endpoint (e.g., caspase activity, cytochrome c release, DNA fragmentation).
• Verify inhibition by measuring caspase-2 activity using fluorogenic substrates (e.g., Ac-VDVAD-AFC) and confirm via immunoblot for cleaved substrates (e.g., PARP).

For more detailed workflow troubleshooting and advanced model integration, see the updated protocols in Caspase-3/7 Inhibitor I, which this article updates with new stability and cross-reactivity findings.

Conclusion & Outlook

Z-VDVAD-FMK is a gold-standard tool for dissecting caspase-2-dependent apoptosis, enabling fine-grained analysis of mitochondrial and caspase signaling pathways in cancer, neurodegenerative, and stress response models. Its irreversible, covalent inhibition mechanism provides high specificity when used at recommended concentrations and storage conditions. However, users should be aware of cross-reactivity, solubility constraints, and non-applicability in pyroptosis or therapeutic contexts. Future work may focus on next-generation inhibitors with improved selectivity and in vivo applicability. For ordering and further product details, visit the official Z-VDVAD-FMK product page at APExBIO.